Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
Executive Summary
The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.
You may also be interested in...
Watson Oxytrol Launch Planned For Mid-2002 As Firm Shifts Focus To Brands
Watson plans to use a marketing partner or contract sales organization to launch its overactive bladder transdermal patch Oxytrol (oxybutynin)
Watson Oxytrol Launch Planned For Mid-2002 As Firm Shifts Focus To Brands
Watson plans to use a marketing partner or contract sales organization to launch its overactive bladder transdermal patch Oxytrol (oxybutynin)
Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts
Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City